Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs Buys 17,000 Shares

Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average price of $5.74 per share, with a total value of $97,580.00. Following the completion of the transaction, the chief executive officer now owns 559,717 shares in the company, valued at $3,212,775.58. The trade was a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Lifecore Biomedical Price Performance

Lifecore Biomedical stock opened at $6.29 on Friday. The company has a market capitalization of $232.89 million, a PE ratio of 78.63 and a beta of 0.98. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90. The stock has a 50-day moving average price of $7.05 and a two-hundred day moving average price of $5.82. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. Analysts expect that Lifecore Biomedical, Inc. will post -0.99 EPS for the current year.

Institutional Trading of Lifecore Biomedical

A number of institutional investors and hedge funds have recently bought and sold shares of LFCR. Marshall Wace LLP grew its position in shares of Lifecore Biomedical by 87.3% in the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after buying an additional 139,887 shares during the last quarter. 272 Capital LP boosted its holdings in Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock valued at $707,000 after acquiring an additional 120,002 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Lifecore Biomedical during the 2nd quarter valued at approximately $327,000. Geode Capital Management LLC lifted its position in shares of Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after purchasing an additional 55,703 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Lifecore Biomedical by 2,640.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after purchasing an additional 52,414 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on LFCR shares. Craig Hallum increased their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 22nd. Stephens restated an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.